Stoke Therapeutics' (STOK) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a research report report published on Tuesday,Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock.

Several other equities analysts also recently commented on STOK. Chardan Capital restated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and a consensus price target of $23.00.

Stoke Therapeutics Trading Down 2.2 %

Stoke Therapeutics stock traded down $0.18 during trading on Tuesday, hitting $8.15. The company had a trading volume of 1,407,236 shares, compared to its average volume of 839,852. Stoke Therapeutics has a 1-year low of $6.29 and a 1-year high of $17.58. The company's 50 day simple moving average is $9.47 and its 200-day simple moving average is $11.42. The stock has a market cap of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99.

Remove Ads

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. As a group, analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company's stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 over the last ninety days. Insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics in the fourth quarter valued at $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $124,000. Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after buying an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $133,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.